San Diego, CA (PRWEB) April 30, 2013

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued keystone Patent No. 8,420,394 titled Culturing Ectodermal Cells Under Reduced Oxygen Tension by the United States Patent and Trademark Office (USPTO). This patent broadly covers Stemedicas proprietary manufacturing process for enhancing the proliferation and differentiation potential of ectodermal cells of any origin. The ectodermal layer gives rise to the cells of the skin and nervous system. The patented process provides Stemedica exclusivity for expanding and manufacturing ischemia tolerant ectodermal cells under reduced oxygen tension.

Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica noted, We are pleased that the USPTO recognizes the uniqueness of the technology and processes to manufacture ectodermal cell of any origin. This includes, but is not limited to: allogeneic and autologous adult, embryonic, parthenogenic and iPS sources of stem cells. When compared to stem cells expanded in normal oxygen, Stemedica cells exhibit superior migratory and engraftment properties, enhanced gap junction formation and a unique gene profile. These critical cell characteristics are the direct result of Stemedicas proprietary technology and expansion methodology.

Alex Kharazi, MD, PhD, Chief Technology Officer at Stemedica noted that, We recently published data from the spinal cord injury study in rats done by Ivan Cheng, MD, at Stanford University showing significant efficacy of Stemedicas neural stem cells injected intrathecally both distally and at the site of injury. We also anticipate publishing extremely promising data in the application of our neural stem cells, mesenchymal stem cells and combined treatment in a mouse model of Alzheimers disease. This large scale animal study was funded by the Swiss government and examines both young and older mice for anatomical and biomarker changes in beta amyloid and tau proteins and brain re-perfusion.

Maynard Howe, PhD, Vice Chairman and Chief Executive Officer of Stemedica commented, While we are pleased to have added another patent to our growing portfolio of intellectual property, we are extremely excited to be issued this keystone patent. It represents the culmination of our research and development, coupled with our cGMP manufacturing processes and our license to make these cells broadly available.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarction, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information please contact Dave McGuigan at dmcguigan (at) stemedica (dot) com

Here is the original post: Stemedica Issued U.S. Patent For Ectodermal Stem Cells

More:
Stemedica Issued U.S. Patent For Ectodermal Stem Cells – Stem ...